SGLT-2 inhibitors reduce heart failure risk across patient groups

Sodium–glucose cotransporter 2 inhibitors are associated with a reduced risk of heart failure compared with dipeptidyl peptidase 4 inhibitors, even in people without a history of cardiovascular disease, a study published in The BMJ has shown.…